“Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s136. doi:10.25251/skin.7.supp.136.